Andrew Spencer

Research interests

Publications

• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2312054

• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2303379

• Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30099-5

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

  Cell Reports · 2017 · https://doi.org/10.1016/j.celrep.2017.02.011

• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1606038

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00389-7

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.2267

• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1505654

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00464-7

• International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.48.7934

• Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(13)70609-0

• International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.47.7901

• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

  Blood · 2011 · https://doi.org/10.1182/blood-2011-06-358812

• Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.3304

• Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.18.8573

• Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

  Leukemia · 2009 · 10.1038/leu.2009.147

• Thalidomide for treatment of multiple myeloma: 10 years later

  Blood · 2008 · 10.1182/blood-2007-10-117457

• Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa070594

• Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.10.5460

• Amyloid Fibril Formation and Seeding by Wild-Type Human Lysozyme and Its Disease-Related Mutational Variants

  Journal of Structural Biology · 2000 · 10.1006/jsbi.2000.4264

• Subcellular Localization of Prostaglandin Endoperoxide H Synthases-1 and -2 by Immunoelectron Microscopy

  Journal of Biological Chemistry · 1998 · 10.1074/jbc.273.16.9886

• Structural and Dynamical Properties of a Denatured Protein. Heteronuclear 3D NMR Experiments and Theoretical Simulations of Lysozyme in 8 M Urea

  Biochemistry · 1997 · 10.1021/bi970049q

• Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse

  Blood · 1994 · 10.1182/blood.v83.11.3377.3377

Current projects

No projects listed.